1 of 1
Story summary
- Roche announced that its obesity drug enicepatide reduced blood sugar and body weight in type-2 diabetes patients.
- The 24-mg dose lowered HbA1c by 2.65% after 48 weeks.
- The same dose yielded an average 15.5% weight loss with no plateau observed.
- About 62% of 447 participants reached HbA1c below 5.7%, entering the non-diabetic range.
- Roche shares fell 0.6% in early Zurich trading after the trial announcement.